Premium
Diameter Assessment of the Third Ventricle with Transcranial Sonography in Patients with Multiple Sclerosis
Author(s) -
Schminke Ulf,
Lorenz Leif,
Kirsch Michael,
Von Sarnowski Bettina,
Khaw Alexander V.,
Kessler Christof,
Dressel Alexander
Publication year - 2010
Publication title -
journal of neuroimaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.822
H-Index - 64
eISSN - 1552-6569
pISSN - 1051-2284
DOI - 10.1111/j.1552-6569.2008.00321.x
Subject(s) - medicine , third ventricle , ventricle , atrophy , magnetic resonance imaging , nuclear medicine , multiple sclerosis , neuroimaging , radiology , pathology , cardiology , psychiatry
BACKGROUND AND PURPOSE Diameter measurement of the third ventricle with magnetic resonance imaging (MRI) and recently also with transcranial sonography (TCS) has emerged as a surrogate marker for brain atrophy and disease progression in multiple sclerosis (MS). This study aims to evaluate TCS measurements of the third ventricle diameter in a clinical routine setting against MRI. METHODS Transverse diameters of the third ventricle were determined in 27 MS patients using both, TCS and MRI. In TCS, the distance between the leading edges of the brain‐ventricle interfaces was assessed in axial image planes. In MRI, the transverse diameter of the mid‐portion of the third ventricle was measured on axial T1‐weighted images. RESULTS The mean diameter of the third ventricle was 4.0 mm (SD 1.7 mm), when measured with MRI, and 4.4 mm (SD 1.7 mm), when measured with TCS. The 95% limits of agreement of the Bland‐Altman Plot were 2.93 mm (95% CI 2.08 to 3.78 mm) and −2.23 mm (95%CI −3.08 to −1.38 mm). Pearson correlation coefficient was .71 ( P < .0001). CONCLUSIONS TCS may appear suitable as screening examination for the extent of brain atrophy at a single‐point study, but at least in the early stages of the disease, TCS is not useful to monitor disease progression. J Neuroimaging 2010;20:53‐57.